Article
A comprehensive study evaluating germline FANCG variants in predisposition to breast and ovarian cancer.
Cancer medicine - 1 Aug 2024
Soukupova Jana, Stastna Barbora, Kanwal Madiha, Hojny Jan, Zemankova Petra, Borecka Marianna, Cerna Leona, Cerna Marta, Cerna Monika, Curtisova Vaclava, Dolezalova Tatana, Duskova Petra, Foretova Lenka, Havranek Ondrej, Horackova Klara, Hovhannisyan Milena, Hruskova Lucie, Chvojka Stepan, Janatova Marketa, Janikova Maria, Jelinkova Sandra, Just Pavel, Kalousova Marta, Kleiblova Petra, Kosarova Marcela, Koudova Monika, Kral Jan, Krausova Michaela, Krutilkova Vera, Machackova Eva, Matejkova Katerina, Michalovska Renata, Nehasil Petr, Nemcova Barbora, Novotny Jan, Palek Matous, Pesek Pavel, Safarikova Marketa, Scheinost Ondrej, Springer Drahomira, Stolarova Lenka, Stranecky Viktor, Subrt Ivan, Tavandzis Spiros, Tureckova Eva, Vesela Kamila, Vlckova Zdenka, Vocka Michal, Zima Tomas, Macurek Libor, Kleibl Zdenek
Abstract excerpt
BACKGROUND: Monoallelic germline pathogenic variants (GPVs) in five Fanconi anemia (FA) genes (BRCA1/FANCS, BRCA2/FANCD1, PALB2/FANCN, BRIP1/FANCJ, and RAD51C/FANCO) confer an increased risk of breast (BC) and/or ovarian (OC) cancer, but the role of GPVs in 17 other FA genes remains unclear. METHODS: Here, we investigated the association of germline variants in FANCG/XRCC9 with BC and OC risk. RESULTS: The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.